Content
04/28/2022
Redwood City, CA USA
Ashvattha Therapeutics
completed $69 million Series B Round funding. Investors include
Natural Capital, Plum Alley Ventures, Tribe Capital.
About
Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from firm founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
